$FNCH News

Last published 2y ago

2y agoFNCHFinch Announces Delisting from Nasdaq and SEC DeregistrationGlobeNewswireBOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (NASDAQ:FNCH) ("Finch" or the "Company"), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today
3y agoFNCHFinch Announces Reverse Stock Split of Common StockGlobeNewswireBOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and
3y agoFNCHFinch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewswireSOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual
3y agoFNCHFinch Therapeutics Announces Executive Leadership TransitionsGlobeNewswireMatthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO effective May 15
3y agoFNCHFinch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License AgreementGlobeNewswireSOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual
3y agoFNCHFinch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesGlobeNewswireSOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual
3y agoFNCHFinch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other AssetsGlobeNewswireSOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the "Company," "Finch," or "Finch Therapeutics") (NASDAQ:FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial
4y agoFNCHFinch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial ResultsGlobeNewswirePatient dosing underway in PRISM4 Phase 3 trial of CP101 in recurrent CDITopline PRISM4 data anticipated in H1 2024 Anticipated cash runway into Q2 2024 SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Finch
4y agoFNCHFinch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx ConferenceGlobeNewswireSOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First
4y agoFNCHFinch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile InfectionGlobeNewswireSOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First
4y agoFNCHFinch Therapeutics Provides Business UpdateGlobeNewswireSOMERVILLE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cl
4y agoFNCHFinch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBDGlobeNewswireSOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cla
4y agoFNCHFinch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial ResultsGlobeNewswireOn track to proceed with enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI in H2 2022 On track to submit IND for FIN-211 in children with autism and significant GI symptoms in Q4 2022 Additional results from PRISM-EXT Phase 2 trial of CP101
4y agoFNCHFinch Therapeutics to Participate in Upcoming June Investor ConferencesGlobeNewswireSOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cla
4y agoFNCHFinch Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireSOMERVILLE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel clas
4y agoFNCH HTGCFinch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial ResultsGlobeNewswireFDA lifted clinical hold on IND for CP101 Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022 $15 million drawn from new $55 million term debt facility Anticipated cash runway into Q2 2024 Corporate update ca
4y agoFNCHFinch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022GlobeNewswireSOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel clas
4y agoBILI DIDI FNCH IQ+1Thinking about buying stock in Finch Therapeutics, Zymeworks, DiDi Global, Bilibili, or IQIYI?PR NewswireNEW YORK, April 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FNCH, ZYME, DIDI, BILI, and IQ. T
4y agoFNCHFinch Therapeutics Announces Removal of FDA Clinical Hold on CP101 INDGlobeNewswireSOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cl
4y agoFNCHFinch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development ProgramsGlobeNewswireSOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cl
4y agoFNCHFinch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdatesGlobeNewswireSOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cl
4y agoFNCHFinch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile InfectionGlobeNewswireSOMERVILLE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics" or "Company") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to devel
4y agoFNCHFinch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines SummitGlobeNewswireSOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cla
4y agoFNCHFinch Therapeutics Announces Additions to Senior Leadership TeamGlobeNewswireBryan Gillis, MBA, appointed Chief Technology Officer Alka Batycky, PhD, appointed Chief Development Officer Howard Franklin, MD, MBA, appointed Senior Vice President, Late-Stage Development and GI Therapeutic Area Lead SOMERVILLE, Mass., Feb. 10
4y agoFNCHFinch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum DisorderGlobeNewswireSOMERVILLE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cla
4y agoFNCHFinch Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect ConferenceGlobeNewswireSOMERVILLE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cla
4y agoFNCHFinch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal OfficerGlobeNewswireSOMERVILLE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cla
5y agoFNCHFinch Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSOMERVILLE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cla
5y agoFNCHFinch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewswireNew positive topline data from 132-participant PRISM-EXT Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI) show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained through 24 weeks New data pres
5y agoFNCHFinch Therapeutics Announces Transition of Chief Medical OfficerGlobeNewswireZain Kassam, MD, MPH to step down as Chief Medical Officer (CMO) and will serve as a special advisor to the company Debra Silberg, MD, PhD to transition from clinical advisor to interim CMO SOMERVILLE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Fin
5y agoFNCHFinch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile InfectionGlobeNewswireNew data from 132-participant PRISM-EXT Phase 2 open-label trial show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained through 24 weeks and a safety profile consistent with previously reported data Aggregated 88.2% sus
5y agoFNCHFinch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific MeetingGlobeNewswireNew data from PRISM3 Phase 2 trial show CP101 demonstrated statistically significant efficacy for prevention of recurrent C. difficile infection and a favorable safety profile through 24 weeks Additional PRISM3 microbiome data show CP101 engraftment le
5y agoFNCHFinch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics SummitGlobeNewswireSOMERVILLE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cla
5y agoFNCHFinch Therapeutics Appoints Samuel Allen Hamood to its Board of DirectorsGlobeNewswireSOMERVILLE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cla
5y agoFNCHFinch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating OfficerGlobeNewswireSOMERVILLE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cl
5y agoFNCHFinch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireSOMERVILLE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cl
5y agoFNCHFinch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireTakeda to accelerate leadership role in advancing FIN-524/TAK-524 ulcerative colitis development program Topline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in open label PRISM-EXT trial expected in H2 2021 Co
5y agoFNCHFinch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development ProgramGlobeNewswireFinch to transfer FIN-524 program to Takeda for clinical development Finch and Takeda to continue discovery efforts targeting Crohn's disease SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "F
5y agoFNCHFinch Therapeutics Added to Russell 2000 and Russell 3000 IndexesGlobeNewswireSOMERVILLE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel cla
5y agoFNCHFinch Therapeutics to Present at Upcoming Virtual Investor ConferencesGlobeNewswireSOMERVILLE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class
5y agoFNCHFinch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewswireCompleted upsized IPO, raising $130.8 million in gross proceeds Topline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in PRISM-EXT expected in H2 2021 Strengthened leadership team with the appointment of Susan E
5y agoFNCHFinch Therapeutics to Participate in the BofA Securities 2021 Virtual Health Care ConferenceGlobeNewswireSOMERVILLE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel clas
5y agoFNCHFinch Therapeutics Appoints Susan E. Graf to Board of DirectorsGlobeNewswireSOMERVILLE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel cl
5y agoFNCHFinch Therapeutics to Participate in the Jefferies Microbiome-Based Therapeutics SummitGlobeNewswireSOMERVILLE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging...
5y agoFNCHFinch Therapeutics Announces Pricing of Upsized Initial Public OfferingGlobeNewswireSOMERVILLE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...